古塞奇尤单抗静脉与皮下诱导治疗克罗恩病12周及96周疗效比较
基于GALAXI 2&3(静脉诱导)和GRAVITI(皮下诱导)研究,通过逆概率加权分析比较古塞奇尤单抗静脉与皮下诱导的疗效。结果显示两种诱导途径在12周临床应答、缓解及生物标志物改善上均无统计学差异,且96周长期疗效不受诱导途径影响,安全性相似。
要点
- 两种途径均在第4周观察到临床应答和缓解,起效迅速
- 96周深度缓解率39.5-51.2%,不受诱导途径影响
核心结论
- 古塞奇尤单抗静脉与皮下诱导治疗中重度活动性克罗恩病疗效相当,96周长期疗效不受诱导途径影响,未发现新的安全性问题。
研究设计与样本
- 基于GALAXI 2&3(静脉诱导)和GRAVITI(皮下诱导)随机对照试验,采用逆概率加权(IPW)分析比较两种诱导途径的疗效,并报告长期扩展研究至96周的结果。
主要发现
- 与安慰剂相比,两种诱导途径在第12周临床应答(Δ 34.5-42.8)、临床缓解(Δ 25.1-34.9)、腹痛评分(Δ 0.6-0.7)和大便频率评分(Δ 1.2-2.0)上均显著更优。
- 两种途径均在第4周观察到临床应答和临床缓解。
- 第96周时,39.5-51.2%的古塞奇尤单抗治疗者达到深度缓解,且不受诱导途径影响。
- 截至第96周,古塞奇尤单抗的不良事件、严重不良事件及导致停药的不良事件暴露调整发生率低于安慰剂,GALAXI与GRAVITI两研究间总体相似。
关键数值与推荐
- 第12周临床应答率差值(Δ 34.5-42.8)、临床缓解率差值(Δ 25.1-34.9)、腹痛评分差值(Δ 0.6-0.7)、大便频率评分差值(Δ 1.2-2.0),均为古塞奇尤单抗 vs 安慰剂。
- 第96周深度缓解率39.5-51.2%(古塞奇尤单抗治疗者)。
临床怎么用
- 静脉或皮下诱导古塞奇尤单抗均可作为中重度活动性克罗恩病的治疗选择,包括高疾病活动度患者。
- 诱导途径不影响96周长期疗效,临床可根据患者偏好和实际情况选择静脉或皮下诱导。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Guselkumab is approved for intravenous (IV) or subcutaneous (SC) induction in moderately to severely active Crohn's disease (CD). We compared outcomes and evaluated the onset of guselkumab efficacy with IV or SC induction and charted the long-term efficacy and safety of guselkumab SC maintenance following either route of induction. METHODS: Treatment effects of IV and SC induction were compared via inverse probability weighting (IPW) analysis. Clinical, endoscopic, and inflammatory biomarker outcomes in participants randomized to placebo or guselkumab in GALAXI (IV induction) and GRAVITI (SC induction) were evaluated through Week 12, including analyses across predefined subgroups. Efficacy and safety outcomes through Week 96 were reported from the long-term extensions (LTEs) of GALAXI and GRAVITI. RESULTS: IPW analysis found no statistical differences (all P > .05) between guselkumab IV and SC induction efficacy. In the per-trial comparisons with placebo, both IV and SC induction were statistically superior for Week 12 clinical response (Δ 34.5-42.8); similar efficacy was seen in Week 12 analyses of clinical remission rates (Δ 25.1-34.9), and abdominal pain (Δ 0.6-0.7) and stool frequency scores (Δ 1.2-2.0). Both routes of guselkumab induction provided rapid onset of efficacy, with clinical response and clinical remission observed by Week 4. IV and SC guselkumab induction regimens were similarly effective at Week 12 across prespecified subgroups of baseline disease location and clinical, endoscopic, and inflammatory biomarker disease activity. Adverse events during induction with SC and IV guselkumab were similar and comparable to placebo. Efficacy was maintained after 96 weeks of guselkumab therapy: long-term outcomes of clinical remission, endoscopic response, endoscopic remission, and deep remission were unaffected by the route of induction: 39.5-51.2% of guselkumab participants achieved deep remission at Week 96. Exposure-adjusted incidence rates of AEs, SAEs, and AEs leading to discontinuation through Week 96 were lower with guselkumab versus placebo and generally similar between GALAXI and GRAVITI. CONCLUSIONS: IV and SC induction with guselkumab were equally effective across a wide range of patients with CD, including those with high baseline disease activity. Efficacy with guselkumab through Week 96 was unaffected by the route of induction. No new safety concerns were identified.
引用
- D'Haens GR, Afzali A, Danese S, et al. Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI. Clin Gastroenterol Hepatol. 2026. PMID: 42946108. doi:10.1016/j.cgh.2026.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。